Bioengineer Gang Bao uses gene editing to repair up to 40 percent of bone marrow cells from patients
Scientists have successfully used gene editing to repair 20 to 40 percent of stem and progenitor cells taken from the peripheral blood of patients with sickle cell disease, according to Rice University bioengineer Gang Bao.
Bao, in collaboration with Baylor College of Medicine, Texas Children’s Hospital and Stanford University, is working to find a cure for the hereditary disease. A single DNA mutation causes the body to make sticky, crescent-shaped red blood cells that contain abnormal hemoglobin and can block blood flow in limbs and organs.
In his talk at the annual American Association for the Advancement of Science meeting in Austin Feb. 16, Bao revealed results from a series of tests to see whether CRISPR/Cas9-based editing can fix the mutation. His presentation was part of a scientific session titled “Gene Editing and Human Identity: Promising Advances and Ethical Challenges.”
“Sickle cell disease is caused by a single mutation in the beta-globin gene (in the stem cell’s DNA),” he said. “The idea is to correct that particular mutation, and then stem cells that have the correction would differentiate into normal blood cells, including red blood cells. Those will then be healthy blood cells.”
Bao’s lab collaborated with Vivien Sheehan, an assistant professor of pediatrics and hematology at Baylor and a member of the sickle cell program at Texas Children’s, to collect stem and progenitor cells (CD34-positive cells) from patients with the disease. These were then edited in the Bao lab with CRISPR/Cas9 together with a custom template, a piece of DNA designed to correct the mutation.
The gene-edited cells were injected into the bone marrow of immunodeficient mice and tested after 19 weeks to see how many retained the edit. “The rate of repair remained stable, which is great,” Bao said. This engraftment study was carried out in the lab of Matt Porteus, an associate professor of pediatrics at Stanford.
Another major finding of the study is that the CRISPR/Cas9 system could introduce large alterations to the genes in patients’ cells, in addition to small mutations or deletions. These off-target effects could cause a disease.
The findings, part of an upcoming paper, are a step toward treating sickle cell disease. Obstacles in the way of a cure include optimizing the CRISPR/Cas9 system to eliminate off-target effects, as well as finding a way to further increase the amount of gene-corrected stem cells.
Bao pointed out that researchers still don’t know whether repairing as much as 40 percent of the cells is enough to cure a patient. “We’d like to say, ‘Yes,’” he said, “but we don’t really know yet. That’s something we hope to learn from an eventual clinical trial.”
The Latest on: Sickle cell disease
via Google News
The Latest on: Sickle cell disease
- Covid-infected man, 69, suffers three-hour erection after disease caused blood clot in his penis before killing himon March 8, 2021 at 3:46 am
The unidentified man, from Ohio, was diagnosed with the condition, known medically as priapism, while in hospital with a severe bout of Covid last autumn.
- Combined liver-cytokine humanization enhances human red blood cell production and survivalon March 6, 2021 at 11:39 am
In a new study by the Yale Department of Immunobiology and Yale Cancer Center, researchers report combined liver and growth factor humanization enhances human red blood cell production and survival in ...
- DNA Fragments Trigger Inflammation in Sickle Cell Diseaseon March 5, 2021 at 1:17 am
Mitochondrial DNA acts as a danger signal in the body and triggers inflammation in people with sickle cell disease, according to a new study. A better understanding of mitochondrial DNA may provide ...
- NIH scientists discover how DNA fragments can trigger inflammation in sickle cell diseaseon March 4, 2021 at 12:10 am
Researchers have discovered that DNA from the mitochondria - the cell’s “powerhouses” - acts as a danger signal in the body and triggers inflammation in people with sickle cell disease. A better ...
- Correction of murine sickle cell disease by allogeneic haematopoietic cell transplantation with anti-3rd party veto cellson March 3, 2021 at 10:35 am
Our data offer a proof of concept for the treatment of SCD by MHC disparate non-myeloablative T cell-depleted HSCT, using anti-3rd party central memory veto CD8-positive T-cells.
- Patients With Sickle Cell Disease Often Overlooked for Life-Saving Kidney Transplantson March 3, 2021 at 5:53 am
People with kidney failure related to sickle cell disease are less likely to receive a transplant than those without sickle cell disease, but it could be life-saving for them, a new study finds.
- sickle cell disease: Addressing a complex world of pain in a single gene differenceon March 1, 2021 at 4:19 pm
A new review analyzes disparities in experience and treatment of sickle cell disease. A single letter difference in a single gene, inherited from both parents, spells a lifetime of anemia and pain for ...
- Transplant beneficial for kidney failure in sickle cellon February 26, 2021 at 2:17 pm
(HealthDay)—Patients with kidney failure who receive a kidney transplant, including those with sickle cell disease, have lower mortality, according to a study published online Feb. 25 in the Clinical ...
- Free medication coming for some Jamaicans with sickle cell diseaseon February 24, 2021 at 8:43 am
Almost 4,000 Jamaicans living with the sickle cell disease are to be allowed to fill their prescriptions for free at Government pharmacies under a new scheme approved by the Cabinet. The good news was ...
- Trial of gene therapy for sickle cell disease haltedon February 24, 2021 at 6:57 am
A clinical trial of a new gene therapy for sickle cell disease that has shown promise has been halted after two participants were diagnosed with cancer.
via Bing News